Analysis of survival by tumor response: have we learnt any better?

被引:9
作者
Ihorst, Gabriele [1 ]
Waldschmidt, Johannes [2 ]
Schumacher, Martin [3 ]
Waesch, Ralph [2 ]
Engelhardt, Monika [1 ]
机构
[1] Univ Med Ctr Freiburg, Ctr Clin Trials, Freiburg, Germany
[2] Univ Med Ctr Freiburg, Dept Hematol & Oncol, D-79106 Freiburg, Germany
[3] Univ Freiburg, Dept Med Biometry & Stat IMBI, D-79106 Freiburg, Germany
关键词
MULTIPLE-MYELOMA; RECOMMENDATIONS;
D O I
10.1007/s00277-015-2426-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1615 / 1616
页数:2
相关论文
共 10 条
[1]   Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables [J].
Anderson, James R. ;
Cain, Kevin C. ;
Gelber, Richard D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :3913-3915
[2]   ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].
ANDERSON, JR ;
CAIN, KC ;
GELBER, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719
[3]   Survival analysis in hematologic malignancies: recommendations for clinicians [J].
Delgado, Julio ;
Pereira, Arturo ;
Villamor, Neus ;
Lopez-Guillermo, Armando ;
Rozman, Ciril .
HAEMATOLOGICA, 2014, 99 (09) :1410-1420
[4]  
Engelhardt M, 2014, RECENT RESULTS CANC, V201, P359, DOI 10.1007/978-3-642-54490-3_22
[5]   European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma [J].
Engelhardt, Monika ;
Terpos, Evangelos ;
Kleber, Martina ;
Gay, Francesca ;
Waesch, Ralph ;
Morgan, Gareth ;
Cavo, Michele ;
van de Donk, Niels ;
Beilhack, Andreas ;
Bruno, Benedetto ;
Johnsen, Hans Erik ;
Hajek, Roman ;
Driessen, Christoph ;
Ludwig, Heinz ;
Beksac, Meral ;
Boccadoro, Mario ;
Straka, Christian ;
Brighen, Sara ;
Gramatzki, Martin ;
Larocca, Alessandra ;
Lokhorst, Henk ;
Magarotto, Valeria ;
Morabito, Fortunato ;
Dimopoulos, Meletios A. ;
Einsele, Hermann ;
Sonneveld, Pieter ;
Palumbo, Antonio .
HAEMATOLOGICA, 2014, 99 (02) :232-242
[6]   Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses [J].
Haas, P. S. ;
Denz, U. ;
Ihorst, G. ;
Engelhardt, M. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (04) :303-309
[7]   Preclinical models of multiple myeloma: a critical appraisal [J].
Schueler, Julia ;
Ewerth, Daniel ;
Waldschmidt, Johannes ;
Waesch, Ralph ;
Engelhardt, Monika .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 :S111-S123
[8]   Surviving survival analysis [J].
Szydlo, RM .
BONE MARROW TRANSPLANTATION, 2001, 28 (10) :907-907
[9]   Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization [J].
Udi, Josefina ;
Schueler, Julia ;
Wider, Dagmar ;
Ihorst, Gabriele ;
Catusse, Julie ;
Waldschmidt, Johannes ;
Schnerch, Dominik ;
Follo, Marie ;
Waesch, Ralph ;
Engelhardt, Monika .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) :104-116
[10]   Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment [J].
Zago, Manola ;
Oehrlein, Katharina ;
Rendl, Corinna ;
Hahn-Ast, Corinna ;
Kanz, Lothar ;
Weisel, Katja .
ANNALS OF HEMATOLOGY, 2014, 93 (12) :1993-1999